Sign Out
For the treatment of cSSTI confirmed or suspected to be caused by Staphylococcus aureus (S. aureus) with a Minimum Inhibitory Concentration (MIC) <2 mg/L to ceftaroline, the dose of ceftaroline fosamil is 600 mg administered every 12 hours by intravenous infusion over 5 to 60 minutes (standard dose), with appropriate reductions for paediatric patients (see Table 10).
For the treatment of patients with cSSTI confirmed or suspected to be caused by S. aureus with an MIC = 2 mg/L to 4 mg/L to ceftaroline, the dose of ceftaroline fosamil is 600 mg administered every 8 hours by intravenous infusion over 120 minutes (high dose), with appropriate reductions for paediatric patients (see Table 10).
Click on icon to see table/diagram/imageSpecial populations: Patients with renal impairment: The dose should be adjusted when creatinine clearance (CrCL) is ≤50 mL/min, as shown in Table 11. Dose recommendations for children and adolescents are based on PK modelling. End Stage Renal Disease (ESRD) patients can only be dosed as in Table 11.
For ESRD, there is insufficient information to recommend dosage adjustments in adolescents aged from 12 to <18 years with bodyweight <33 kg and in children aged from 2 to 12 years. There is insufficient information to recommend dosage adjustments in paediatric patients <2 years with moderate or severe renal impairment or ESRD. (See Table 11.)
Click on icon to see table/diagram/imagePatients with hepatic impairment: No dosage adjustment is considered necessary in patients with hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Elderly patients: No dosage adjustment is required for the elderly with creatinine clearance (CrCL) values >50 mL/min (see Pharmacology: Pharmacokinetics under Actions).
Reconstitution and compatibility: See Special precautions for disposal and other handling under Cautions for Usage.
